By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

A High Price for Rare Cancer Drugs
Pay For Performance and HCAHPS
United States Third Lowest Spender on Health Care in 11 Developed Countries
Why Transparency Matters More Than Ever
The Daraprim Debacle – The Smell Test Sniffs Out Price Gouging.

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

What Are the Steps to Obtain Health Equity Accreditation?
What Are the Steps to Obtain Health Equity Accreditation?
Health
December 18, 2025
a cosmetologist doing beauty treatment to a woman
Compliance Regulations for Aesthetic Clinics in the EU
Health Women Health
December 18, 2025
sunlit portrait with delicate lace shadows
Dr. Michael Piepkorn: Understanding The Genetic Links Behind Familial Skin Cancer
Skin
December 17, 2025
post-surgical recovery
Your Guide To Key Milestones In At Home Post-Surgical Recovery
Health Infographics
December 14, 2025

You Might also Like

patient empowerment
BusinessHealth ReformMobile HealthNewsPolicy & LawTechnology

How Health Innovators Can Foster Patient Empowerment

May 7, 2014

Health Care Costs and the Medical Malpractice Myth

January 21, 2014

Uninsured Fall Head First Into Gaping Coverage Gap

October 21, 2013
Physician Marketing, Online Marketing, LinkedIn
BusinesseHealthSocial Media

5 Ways LinkedIn Helps Physicians in Marketing Their Practice

April 11, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?